10
Participants
Start Date
February 27, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2027
Pasireotide
Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
SF-36 and HADS
Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
RECRUITING
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale
RECRUITING
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
RECRUITING
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
RECRUITING
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
RECRUITING
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RECORDATI GROUP
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER